Our Top Picks For Psychedelics Stocks
COMPASS Pathways (NASDAQ: CMPS)
Compass Pathways stock is a pure-play way to invest in psilocybin therapeutics. The company wants to treat severe depression with psilocybin medicine. CMPS is developing psychedelic therapy called psilocybin (COMP360) to treat treatment-resistant depression. Compass Pathways has the backing of billionaire tech-investor Peter Thiel with a 10 million euro stake.
ATAI Life Sciences (NASDAQ: ATAI)
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The company is backed by Peter Thiel.
MindMed (NASDAQ: MNMD)
MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. MindMed is backed by Canopy Growth founder Bruce Linton and Kevin O’Leary